Protalix BioTherapeutics, Inc. (PLX)
NYSEAMERICAN: PLX · Real-Time Price · USD
2.970
+0.110 (3.85%)
Feb 13, 2026, 4:00 PM EST - Market closed
Protalix BioTherapeutics Revenue
Protalix BioTherapeutics had revenue of $17.85M in the quarter ending September 30, 2025, a decrease of -0.60%. This brings the company's revenue in the last twelve months to $61.84M, up 35.42% year-over-year. In the year 2024, Protalix BioTherapeutics had annual revenue of $53.40M, down -18.47%.
Revenue (ttm)
$61.84M
Revenue Growth
+35.42%
P/S Ratio
3.66
Revenue / Employee
$290,329
Employees
213
Market Cap
238.85M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 53.40M | -12.10M | -18.47% |
| Dec 31, 2023 | 65.49M | 17.86M | 37.48% |
| Dec 31, 2022 | 47.64M | 9.29M | 24.22% |
| Dec 31, 2021 | 38.35M | -24.55M | -39.03% |
| Dec 31, 2020 | 62.90M | 8.21M | 15.00% |
| Dec 31, 2019 | 54.69M | 20.45M | 59.73% |
| Dec 31, 2018 | 34.24M | 13.16M | 62.44% |
| Dec 31, 2017 | 21.08M | 11.88M | 129.13% |
| Dec 31, 2016 | 9.20M | 4.84M | 110.79% |
| Dec 31, 2015 | 4.36M | 841.00K | 23.87% |
| Dec 31, 2014 | 3.52M | - | - |
| Dec 31, 2013 | 0 | - | - |
| Dec 31, 2012 | 34.87M | 26.48M | 315.81% |
| Dec 31, 2011 | 8.39M | 1.74M | 26.26% |
| Dec 31, 2010 | 6.64M | 6.25M | 1,611.86% |
| Dec 31, 2009 | 388.00K | - | - |
| Dec 31, 2008 | - | - | - |
| Dec 31, 2007 | - | - | - |
| Dec 31, 2006 | - | - | - |
| Dec 31, 2005 | 150.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Coherus Oncology | 277.73M |
| Silence Therapeutics | 25.83M |
| OmniAb | 21.09M |
| MediWound | 20.93M |
| Opus Genetics | 14.63M |
| Camp4 Therapeutics | 3.80M |
| Orchestra BioMed Holdings | 2.82M |
| Inhibikase Therapeutics | 1.00 |
PLX News
- 12 days ago - A March Decision That Could Change Protalix BioTherapeutics Outlook - Seeking Alpha
- 15 days ago - Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa) in the EU - GlobeNewsWire
- 15 days ago - Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of 2mg/kg Body Weight Every-Four-Weeks for Elfabrio® (pegunigalsidase alfa) ▼ in the EU - GlobeNewsWire
- 5 weeks ago - Protalix BioTherapeutics Letter to Stockholders - PRNewsWire
- 2 months ago - Protalix Biotherapeutics and Secarna Pharmaceuticals Enter into Collaboration and Option Agreement - PRNewsWire
- 3 months ago - Protalix BioTherapeutics, Inc. (PLX) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Protalix BioTherapeutics Reports Third Quarter 2025 Financial and Business Results - PRNewsWire
- 3 months ago - Protalix BioTherapeutics to Announce Third Quarter 2025 Financial and Business Results on November 13, 2025 - PRNewsWire